Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Beating Bribery and Corruption in the Life Sciences: The Big Picture

  • Broadcast in Business
  • 0 comments
IQPC_London

IQPC_London

×  

Follow This Show

If you liked this show, you should follow IQPC_London.
h:126125
s:1264995
archived
Paul Vincke, President of the European Healthcare Fraud and Corruption Network, and a civil servant at the Ministry of Health in Belgium, outlines recent developments in anti-corruption and bribery legislation in the pharmaceuticals industry. The UK Bribery Bill: Issued in April 2010, the Act is due to come into force in April 2011. As this is one of the biggest developments in this area for years, we ask Paul how he interprets the delays in enforcing this legislation, what the implications of the Act will be on the ways companies conduct their business in the future, and why is it important to revise compliance policy even in advance of the UK Bribery Act enforcement. The Global Picture: The unique challenges the Life Sciences industry faces in relation to Bribery and Corruption; Whether the role of corporate whistle-blowing has changed in corporate bribery cases and if so, how; What companies and industries must do in order to achieve the best outcomes in trials; And the most important things to keep in mind when developing and monitoring a compliance policy. Paul will be speaking at the forthcoming conference: Global Corruption and Bribery Compliance for the Life Sciences. If you think you’d benefit from attending this event, you can find out more about the agenda from the website: www.corruptioncomplianceforum.com or by contacting the enquires team direct on 0800 652 2363 or email enquire@iqpc.co.uk.

Comments

 comments